GLYC - GlycoMimetics Inc Stock Price, Fair Value and News

$13.09-1.18 (-8.27%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

GLYC Price Action

Last 7 days

15.2%

Last 30 days

20.4%

Last 90 days

-13.3%

Trailing 12 Months

-51.9%

GLYC RSI Chart

GLYC Valuation

Market Cap

181.9M

Price/Earnings (Trailing)

-2.64

Price/Sales (Trailing)

1.9K

EV/EBITDA

8.49

Price/Free Cashflow

-3.56

GLYC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

GLYC Fundamentals

GLYC Revenue

Revenue (TTM)

92.6K

Rev. Growth (Yr)

614.54%

Rev. Growth (Qtr)

308.31%

GLYC Earnings

Earnings (TTM)

-68.8M

Earnings Growth (Yr)

-150.47%

Earnings Growth (Qtr)

-12.93%

GLYC Profitability

EBT Margin

4961.38%

Return on Equity

-58.96%

Return on Assets

-49.73%

Free Cashflow Yield

-28.09%

GLYC Investor Care

Shares Dilution (1Y)

2054.41%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	0	0	0	0
2023	0	0	0	0
2022	0	179.3K	179.2K	92.6K
2021	2.2M	2.2M	1.3M	1.2M
2020	29.1M	9.0M	10.0M	10.2M
2015	0	35.1M	20.0M	20.1M
2014	0	6.8M	12.3M	15.0M
2013	12.4M	9.6M	6.8M	4.0M
2012	0	0	0	15.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

CEO	Mr. Harout Semerjian
WEBSITE	glycomimetics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	38

GlycoMimetics Inc Frequently Asked Questions

What is the ticker symbol for GlycoMimetics Inc? What does GLYC stand for in stocks?

GLYC is the stock ticker symbol of GlycoMimetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GlycoMimetics Inc (GLYC)?

As of Tue Dec 02 2025, market cap of GlycoMimetics Inc is 181.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLYC stock?

You can check GLYC's fair value in chart for subscribers.

Is GlycoMimetics Inc a good stock to buy?

The fair value guage provides a quick view whether GLYC is over valued or under valued. Whether GlycoMimetics Inc is cheap or expensive depends on the assumptions which impact GlycoMimetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLYC.

What is GlycoMimetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 02 2025, GLYC's PE ratio (Price to Earnings) is -2.64 and Price to Sales (PS) ratio is 1.86 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GLYC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on GlycoMimetics Inc's stock?

In the past 10 years, GlycoMimetics Inc has provided -0.317 (multiply by 100 for percentage) rate of return.